Antisense strategies in dopamine receptor pharmacology

Life Sciences

Volumn 60, Issue 7, 1997, Pages 433-455

  Weiss, Benjamin ^a   Zhang, Sui Po ^a   Zhou, Long Wu ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine; antisense; antisense localization; body temperature; D1 dopamine receptor; D2 dopamine receptor; D3 dopamine receptor; dopamine receptor; dopamine receptor mRNA; dopamine receptor pools; dopamine receptor subtypes; dopaminergic behavior; fluphenazine N mustard; intraventricular; molecular biology; oligodeoxynucleotide; quinpirole; receptor synthesis; SKF 38393

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; MESSENGER RNA; NEUROTRANSMITTER RECEPTOR; OXOTREMORINE; QUINPIROLE; RECEPTOR SUBTYPE;

BEHAVIOR; BRAIN; DOPAMINERGIC TRANSMISSION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG UPTAKE; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; RODENT; TURNOVER TIME;

RODENTIA;

EID: 0031561793     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(96)00566-8     Document Type: Short Survey

References (110)

1. 1. B. WEISS and E. COSTA, Science 156 1750-1752 (1967).
2. 2. B. WEISS, J. Pharmacol. Exp. Ther. 168 146-152 (1969).
3. 3. S.J. STRADA and B. WEISS, Arch. Biochem. and Biophysic. 160 197-204 (1974).
4. 4. B. WEISS, L. GREENBERG and M. BLAIR CLARK, , Israel Hanin (ed), 319-329, Raven Press, New York (1984).
5. 5. J.D. WINKLER, K. CALLISON, S. CASS and B. WEISS, Neuropharmacology 27 439-442 (1988).
6. 6. L.W. ZHOU, Z.H. QIN and B. WEISS, Neuropsychopharmacol. 4 47-55 (1991).
7. 7. A. CARLSSON, Neuropsychopharmacology 1 179-186 (1988).
8. 8. P. SEEMAN, N.H. BZOWEJ, H-C. GUAN, C. BERGERON, G.P. REYNOLDS, E.D. BIRD, P. RIEDERER, K. JELLINGER and W.W. TOURTELLOTTE, Neuropsychopharmacology 1 5-15 (1987).
9. 9. V.L. DAWSON, T.M. DAWSON and J.K. WAMSLEY, Brain. Res. Bull. 25 903-912 (1990).
10. 10. L.-W. ZHOU, S.-P. ZHANG, T.A. CONNELL and B. WEISS, J. Pharmacol. Exp. Ther. 264 824-830 (1993).
11. 11. B.K. YAMAMOTO and S. DAVY, J. Neurochem. 58 1736-1742 (1992).
12. 12. Z.-H. QIN, L.-W. ZHOU and B. WEISS, Neuroscience 60 97-114 (1994).
13. 13. Z.-H. QIN and B. WEISS, Eur. J. Pharmacol. Mol. Pharmacol. 269 25-33 (1994).
14. 14. Z.-H. QIN, S.-P. ZHANG and B. WEISS, Mol. Brain Res. 21 293-302 (1994).
15. 15. B.J. MORRIS and S.P. HUNT, Neurosci. Lett. 125 201-204 (1991).
16. 16. J.F. CHEN, V.J. ALOYO and B. WEISS, Neuroscience 54 669-680 (1993).
17. 17. J.A. ANGULO, H. COIRINI, M. LEDOUX and M. SCHUMACHER, Mol. Brain Research 11 161-166 (1991).
18. 18. C.R. GERFEN, T.M. ENGBER, L.C. MAHAN, Z. SUSEL, T.N. CHASE, F.J. MONSMA, JR. and D.R. SIBLEY, Science 250 1429-1432 (1990).
19. 19. J. KOPP, N. LINDEFORS, S. BRENE, H. HALL, H. PERSON and G. SEDVALL, Neuroscience 47 771-779 (1992).
20. 20. P. ROGUE, A. HANAUER, J. ZWILLER, A.N. MALVIYA and G. VINCENDON, Eur. J. Pharmacol. 207 165-168 (1991).
21. 21. B. WEISS, L.W. ZHOU, J.F. CHEN, F. SZELE and G. BAI, Adv. Biosci. 77 9-25 (1990).
22. 22. J.W. KEBABIAN and D.B. CALNE, Nature 277 93-96 (1979).
23. 23. P.P. SPANO, S. GOVONI and M. TRABUCCHI, Adv. Biochem. Psychopharmacol. 19 155-165 (1978).
24. 24. O. CIVELLI, J.R. BUNZOW, D.K. GRANDY, Q.-Y. ZHOU and H.H.M. VAN TOL, Eur. J. Pharmacol. Mol. Pharmacol. 207 277-286 (1991).
25. 25. J.A. GINGRICH and M.G. CARON, Annu. Rev. Neurosci. 16 299-321 (1993).
26. 26. K.J. MACK, R.D. TODD and K.L. O'MALLEY, J. Neurochem. 57 795-801 (1991).
27. 27. P. SEEMAN, H.-C. GUAN, H.H.M. VAN TOL and H.B. NIZNIK, Synapse 14 247-253 (1993).
28. 28. P. SEEMAN, Neuropsychopharmacology 7 261-284 (1992).
29. 29. D.R. SIBLEY and F.J. MONSMA, JR., Trends Pharmacol. Sci. 13 61-69 (1992).
30. 30. J.R. BUNZOW, H.H.M. VAN TOL, D.K. GRANDY, P. ALBERT, J. SALON, C. MACDONALD, C.A. MACHIDA, K.A. NEVE and O. CIVELLI, Nature 336 783-787 (1988).
31. 31. F.J. MONSMA,JR., L.D. MCVITTIE, C.R. GERFEN, L.C. MAHAN and D.R. SIBLEY, Nature 342 926-929 (1989).
32. 32. C.S. FISHBURN, D. BELLELI, C. DAVID, S. CARMON and S. FUCHS, J. Biol. Chem. 268 5872-5878 (1993).
33. 33. B. GIROS, M-P. MARTRES, C. PILON, P. SOKOLOFF and J-C. SCHWARTZ, Biochem. Biophys. Res. Comm. 176 1584-1592 (1991).
34. 34. J.-C. SCHWARTZ, D. LEVESQUE, M.-P. MARTRES and P. SOKOLOFF, Clin. Neuropharmacol. 16 295-314 (1993).
35. 35. D.M. WEINER, A.I. LEVEY, R.K. SUNAHARA, H.B. NIZNIK, B.F. O'DOWD, P. SEEMAN and M.R. BRANN, Proc. Natl. Acad. Sci. U. S. A. 88 1859-1863 (1991).
36. 36. J.F. CHEN, Z.H. QIN, F. SZELE, G. BAI and B. WEISS, Neuropharmacology 30 927-941 (1991).
37. 37. A. MANSOUR, J.H. MEADOR-WOODRUFF, J.R. BUNZOW, O. CIVELLI, H. AKIL and S.J. WATSON, J. Neurosci. 10 2587-2600 (1990).
38. 38. M.-L. BOUTHENET, E. SOUIL, M.-P. MARTRES, P. SOKOLOFF, B. GIROS and J.-C. SCHWARTZ, Brain Res. 564 203-219 (1991).
39. 39. B. LANDWEHRMEYER, G. MENGOD and J.M. PALACIOS, Eur. J. Neurosci. 5 145-153 (1993).
40. 40. P. SOKOLOFF, B. GIROS, M-P. MARTRES, M-L. BOUTHENET and J-C. SCHWARTZ, Nature 347 146-151 (1990).
41. 41 H.H.M. VAN TOL, J.R. BUNZOW, H.C. GUAN, R.K. SUNAHARA, P. SEEMAN, H.B. NIZNIK and O. CIVELLI, Nature 350 614-619 (1991).
42. 42. R.K. SUNAHARA, H-C. GUAN, B.F. O'DOWD, P. SEEMAN, L.G. LAURIER, G. NG, S. GEORGE, J. TORCHIA, H.H.M. VAN TOL and H.B. NIZNIK, Nature 350 614-619 (1991).
43. 43. M. TIBERI, K.R. JARVIE, C. SILVIA, P. FALARDEAU, J.A. GINGRICH, N. GODINOT, L. BERTRAND, T.L. YANG-FENG, R.T. FREMEAU,JR. and M.G. CARON, Proc. Natl. Acad. Sci. U. S. A. 88 7491-7495 (1991).
44. 44. J.F. CHEN and B. WEISS, Dev. Brain Res. 63 95-104 (1991).
45. 45. B. WEISS, J.F. CHEN, S. ZHANG and L.-W. ZHOU, Neurochem. Int. 20 Suppl. 49S-58S (1992).
46. 46. E.R. MESCO, S.G. CARLSON, J.A. JOSEPH and G.S. ROTH, Mol. Brain Res. 17 160-162 (1993).
47. 47. P.R. BUCKLAND, M.C. O'DONOVAN and P. MCGUFFIN, Psychopharmacology 106 479-483 (1992).
48. 48. L.K. SRIVASTAVA, M.A. MORENCY, S.B. BAJWA and R.K. MISHRA, J. Mol. Neurosci. 2 155-161 (1990).
49. 49. C. HELENE, Eur. J. Cancer 27 1466-1471 (1991).
50. 50. E.L. WICKSTROM, T.A. BACON, A. GONZALEZ, D.L. FREEMAN and G.H. LYMAN, Proc. Natl. Acad. Sci. USA 85 1028-1032 (1988).
51. 51. S. AGRAWAL, TIBTECH. 10 152-158 (1992).
52. 52. J.S. COHEN (ED), Oligodeoxynucleotides-Antisense Inhibitors of Gene Expression, p.23, MacMillan, New York (1993).
53. 53. D. EILAM and H. SZECHTMAN, Eur. J. Pharmacol. 161 151-157 (1989).
54. 54. C.A. STEIN and Y.-C. CHENG, Science 261 1004-1012 (1993).
55. 55. J. HYTTEL, Eur. J. Pharmacol. 91 153-154 (1983).
56. 56. J.F. CHEN and B. WEISS, Neurosci. Lett. 150 215-218 (1993).
57. 57. P.I. TIEDTKE, C. BISCHOFF and W.J. SCHMIDT, J. Neural. Transm. Gen. Sect. 81 173-182 (1990).
58. 58. J. WILLETTS, R.L. BALSTER and J.D. LEANDER, TIPS 11 423-428 (1990).
59. 59. G.R. BREESE and R.A. MUELLER, Eur. J. Pharmacol. 113 109-114 (1985).
60. 60. M.T. PUGH, K.M. O'BOYLE, A.G. MOLLOY and J.L. WADDINGTON, Psychopharmacology (Berlin) 87 308-312 (1985).
61. 61. S. AGRAWAL, J. TEMSAMANI and J.Y. TANG, Proc. Natl. Acad. Sci. U. S. A. 88 7595-7599 (1991).
62. 62. A. CACERES and K.S. KOSIK, Nature 343 461-463 (1990).
63. 63. S.T. CROOKE, Annu. Rev. Pharmacol. Toxicol. 32 329-376 (1992).
64. 64. A. AKABAYASHI, C. WAHLESTEDT, J.T. ALEXANDER and S.F. LEIBOWITZ, Mol. Brain Res. 21 55-61 (1994).
65. 65. R. GYURKO, D. WIELBO and M.I. PHILLIPS, Regul. Pept. 49 167-174 (1993).
66. 66. M.M. MCCARTHY, E.H. SCHLENKER and D.W. PFAFF, Endocrinology 133 433-439 (1993).
67. 67. S. OGAWA, U.E. OLAZABAL, I.S. PARHAR and D.W. PFAFF, J. Neurosci. 14 1766-1774 (1994).
68. 68. A. OSEN-SAND, M. CATSICAS, J.K. STAPLE, K.A. JONES, G. AYALA, J. KNOWLES, G. GRENNINGLOH and S. CATSICAS, Nature 364 445-448 (1993).
69. 69. R.R. SAKAI, P.P. HE, X.D. YANG, L.Y. MA, Y.F. GUO, J.J. REILLY, C.N. MOGA and S.J. FLUHARTY, J. Neurochem. 62 2053-2056 (1994).
70. 70. M. SIMONS, E.R. EDELMAN, J.-L. DEKEYSER, R. LANGER and R.D. ROSENBERG, Nature 359 67-70 (1992).
71. 71. T. SKUTELLA, J.C. PROBST, G.F. JIRIKOWSKI, F. HOLSBOER and R. SPANAGEL, Neurosci. Lett. 167 55-58 (1994).
72. 72. K.M. STANDIFER, C.-C. CHIEN, C. WAHLESTEDT, G.P. BROWN and G.W. PASTERNAK, Neuron 12 805-810 (1994).
73. 73. C. WAHLESTEDT, E. GOLANOV, S. YAMAMOTO, F. YEE, H. ERICSON, H. YOO, C.E. INTURRISI and D.J. REIS, Nature 363 260-263 (1993).
74. 74. B.J. CHIASSON, M.L. HOOPER, P.R. MURPHY and H.A. ROBERTSON, Eur. J. Pharmacol. Mol. Pharmacol. 227 451-453 (1992).
75. 75. A. VALERIO, A. ALBERICI, C. TINTI, P. SPANO and M. MEMO, J. Neurochem. 62 1260-1266 (1994).
76. 76. B. WEISS, L.-W. ZHOU, S.-P. ZHANG and Z.-H. QIN, Neuroscience 55 607-612 (1993).
77. 77. M. ZHANG and I. CREESE, Neurosci. Lett. 161 223-226 (1993).
78. 78. L.-W. ZHOU, S.-P. ZHANG, Z.-H. QIN and B. WEISS, J. Pharmacol. Exp. Ther. (1994).
79. 79. J. OTT and F. ECKSTEIN, Biochemistry 26 8237-8241 (1987).
80. 80. S. AGRAWAL, S.H. MAYRAND, P.C. ZAMECNIK and T. PEDERSON, Proc. Natl. Acad. Sci. U. S. A. 87 1401-1405 (1990).
81. 81. J.M. CAMPBELL, T.A. BACON and E. WICKSTROM, J. Biochem. Biophys. Meth. 20 259-267 (1990).
82. 82. P. IVERSEN, Anti-Cancer Drug Design 6 531-538 (1991).
83. 83. A.R. VAN DER KROL, J.N. MOL and A.R. STUITJE, Gene 72 45-50 (1988).
84. 84. A. TEICHMAN-WEINBERG, U.Z. LITTAUER and I. GINZBURG, Gene 72 297-307 (1988).
85. 85. C. J. MARCUS-SEKURA, Anal. Biochem. 172 289-295 (1988).
86. 86. S.-P. ZHANG, L.-W. ZHOU, R.C.S. LIN and B. WEISS, Soc. Neurosci. 21 149.8 (1995).
87. 87. A. SZKLARCZYK and L. KACZMAREK, J. Neurosci. Methods 60 181-187 (1995).
88. 88. P. YASWEN, M.R. STAMPFER, K. GOSH and J. COHEN, Antisense Res. Dev. 3 67-77 (1993).
89. 89. S.-P. ZHANG, L.-W. ZHOU and B. WEISS, J. Pharmacol. Exp. Ther. 271 1462-1470 (1994).
90. 90. J.E. FAUNT and A.D. CROOKER, Eur. J. Pharmacol. 733 243-247 (1987).
91. 91. C.P. SILVIA, G.R. KING, T.H. LEE, Z.-Y. XUE, M.G. CARON and E.H. ELLINWOOD, Mol. Pharmacol. 46 51-57 (1994).
92. 92. C.B. HUBNER and J.E. MORETON, Psychopharmacology (Berlin) 105 151-156 (1991).
93. 93. D.C.S. ROBERTS and R. RANALDI, Clin. Neuropharmacol. 18,Suppl,1. S84-S95 (1995).
94. 94. H. NISSBRANDT, A. EKMAN, E. ERIKSSON and M. HEILIG, Neuroreport 6 573-576 (1995).
95. 95. T.M. ENGBER, C. MARIN, Z. SUSEL and T.N. CHASE, Eur. J. Pharmacol. 236 385-393 (1993).
96. 96. D.A. STAUNTON, B.B. WOLFE, P.M. GROVES and P.B. MOLLINOFF, Brain Res. 211 315-327 (1981).
97. 97. J.D. WINKLER and B. WEISS, J. Pharmacol. Exp. Ther. 249 507-516 (1989).
98. 98. L.-W. ZHOU, S.-P. ZHANG, T.A. CONNELL and B. WEISS, Neurochem. Int. 22 301-311 (1993).
99. 99. I. CREESE, D.R. BURT and S.H. SNYDER, Science 197 596-598 (1977).
100. 100. R.J. MANDEL, S.L. HARTGRAVES, J.A. SEVERSON, J.J. WOODWARD, R.E. WILCOX and P.K. RANDALL, Behav. Brain Res. 59 53-64 (1993).
101. 101. I. CREESE, D.R. SIBLEY and S.X. XU, Neurochem. Int. 20 Suppl. 45S-48S (1992).
102. 102. Z.-H. QIN, J.F. CHEN and B. WEISS, J. Neurochem. 62 411-420 (1994).
103. 103. J.D. WINKLER, K. THERMOS and B. WEISS, Psychopharmacology 92 285-291 (1987).
104. 104. K. THERMOS, J.D. WINKLER and B. WEISS, Neuropharmacology 26 1473-1480 (1987).
105. 105. A. BOURSON, E. BORRONI, R.H. AUSTIN, F.J.J. MONSMA and A.J. SLEIGHT, J. Pharmacol. Exp. Ther. 257 173-180 (1995).
106. 106. K.M. STANDIFER, C.-C. CHIEN, C. WAHLESTEDT, G.P. BROWN and G.W. PASTERNAK, Neuron 12 805-810 (1994).
107. 107. G. BATTAGLIA, A.B. NORMAN, E.J. HESS and I. CREESE, Neurosci. Lett. 69 290-295 (1986).
108. 108. S.E. SENOGLES, J. Biol. Chem. 269 23120-23127 (1994).
109. 109. D. MALEK, G. MUNCH and D. PALM, FEBS Lett. 325 215-219 (1993).
110. 110. Z.-H. QIN, L.-W. ZHOU, S.-P. ZHANG, Y. WANG and B. WEISS, J. Pharmacol. Exp. Ther. 48 730-737 (1995).